AstraZeneca presents further data showing the interconnectivity between cardiovascular and renal risks in diabetes at EASD 2018
Pressmeddelanden • Sep 20, 2018 12:26 CEST
AstraZeneca and MedImmune, its global biologics research and development arm, will present more than 50 abstracts from the Company’s Cardiovascular, Renal & Metabolism (CVRM) therapy area at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany, 1-5 October 2018.
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Pressmeddelanden • Sep 18, 2018 08:04 CEST
AstraZeneca today announced results from the BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed one of the two pivotal SIROCCO or CALIMA Phase III trials.
The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
Pressmeddelanden • Sep 16, 2018 17:29 CEST
Data from the KRONOS trial presented at the European Respiratory Society (ERS) International Congress 2018
US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia
Pressmeddelanden • Sep 13, 2018 22:18 CEST
AstraZeneca and MedImmune, announced today that the US FDA has approved Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.Lumoxiti is not recommended in patients with severe renal impairment (CrCl ≤ 29 mL/min).
AstraZeneca to present Fasenra long-term safety and efficacy data at European Respiratory Society International Congress 2018
Pressmeddelanden • Sep 13, 2018 08:04 CEST
AstraZeneca and MedImmune, today announced that new data from the BORA Phase III extension trial of Fasenra (benralizumab) is among 43 company abstracts accepted for oral and poster presentation at the European Respiratory Society (ERS) International Congress 2018, 15-19 September in Paris.
Pressmeddelanden • Sep 07, 2018 08:03 CEST
AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.
Pressmeddelanden • Aug 31, 2018 08:04 CEST
AstraZeneca and MedImmune, today announced top-line results from the TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). The trial did not meet the primary endpoint of a statistically-significant reduction in disease activity in patients with SLEas measured by the SLE Responder Index 4 (SRI4)at 12 months.
European Commission approves new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 diabetes
Pressmeddelanden • Aug 30, 2018 08:02 CEST
AstraZeneca today announced that the European Commission (EC) has approved Bydureon BCise (exenatide 2mg prolonged-release suspension for injection in pre-filled pen) as a new formulation within the marketing authorisation for Bydureon (exenatide extended release) for the treatment of patients with type-2 diabetes.
AstraZeneca provides update on AERISTO Phase IIIb trial for Bevespi Aerosphere in chronic obstructive pulmonary disease
Pressmeddelanden • Aug 23, 2018 14:08 CEST
AstraZeneca today announced top-line results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Pressmeddelanden • Aug 21, 2018 08:01 CEST
AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), following priority review.
AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018
Pressmeddelanden • Aug 20, 2018 08:02 CEST
New evidence of the persistency of ischaemic risk in post-heart attack patients, highlighting specific risk factors that may help identify patients for extended DAPT Latest data on the links between RAAS inhibitor dose reduction and increased risk of mortality and MACE in heart failure patients with hyperkalaemia
Pressmeddelanden • Aug 03, 2018 08:19 CEST
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
Imfinzi receives positive EU CHMP opinion for locally- advanced, unresectable non-small cell lung cancer
Pressmeddelanden • Jul 27, 2018 15:03 CEST
Recommended marketing authorisation for patients whose tumours express PD-L1 on ≥1% of tumour cells Imfinzi is the first immunotherapy recommended for approval for the treatment of locally-advanced, unresectable NSCLC
Pressmeddelanden • Jul 26, 2018 08:06 CEST
Starka resultat från nya läkemedel och tillväxtmarknaderna stödjer återgång till tillväxt under 2018
Pressmeddelanden • Jul 24, 2018 08:12 CEST
AstraZeneca has agreed to sell the commercial rights to Atacand(candesartan cilexetil)and AtacandPlus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to CheplapharmArzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine for the treatment of heart failure and hypertension.
Pressmeddelanden • Jul 16, 2018 13:22 CEST
AstraZeneca meddelar i dag att Katarina Ageborg utsetts till ny VD för AstraZeneca AB. Hon tar över efter Jan-Olof Jacke den 1 augusti 2018 och kommer även fortsättningsvis rapportera till koncernchef Pascal Soriot.
Pressmeddelanden • Jul 02, 2018 08:03 CEST
Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Second approval in Japan for AstraZeneca and MSD’s Lynparza
Pressmeddelanden • Jul 02, 2018 08:02 CEST
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi (durvalumab) as maintenance therapy after definitive chemoradiation therapy (CRT) in locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC).
Pressmeddelanden • Jun 29, 2018 16:09 CEST
AstraZeneca today announced that the CHMP of the European Medicines Agency (EMA) has adopted a positive opinion, recommending inclusion of Bydureon (2mg prolonged-release suspension for injection) BCise device as a new formulation within the marketing authorisation for Bydureon (exenatide extended-release) for the treatment of type-2 diabetes.
Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer
Pressmeddelanden • Jun 27, 2018 08:02 CEST
AstraZeneca and MSD today announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets.